Tackling the tricky problem of antidepressant treatment
in childhood
There is a discussion in the 8 April issue of the New England Journal of Medicine concerning the rather tricky problem of antidepressant medication of children, from the US National Institute of Mental Health. In Britain, physicians have been warned to avoid the use of paroxetine generally in treating depressed children younger than 18 years. In the US, the Food and Drug Administration has cautioned that paroxetine therapy should not be discontinued abruptly, from fear of severe withdrawal reactions.
The NEJM article asks whether selective serotonin reuptake inhibitors
increase the risk of inducing suicidal behaviour in depressed children.
When they were first introduced they were judged superior to earlier
antidepressants, being better tolerated and presenting less hazard if
taken in overdose. The FDA in the US has given its approval to fluvoxamine,
sertraline and fluoxetine for children suffering from major depressive
disorders, provided they are older than 8 years. In addition to these,
however, paroxetine, citalopram and venlafaxine have been prescribed
by US doctors.
Depressed children usually suffer from the sadness, apathy and lack of
energy seen in adults, but some manifest only irritability or social
isolation syndrome. By their late teens, children aged 10 to 19 who have
been treated with antidepressants have shown a higher suicide rate than
others. Nevertheless, for obsessive-compulsive disorder, fluvoxamine,
sertraline and fluoxetine have proved helpful, although they may induce
behavioural abnormalities in some. The efficacy of fluoxetine has been
proven in children, and increased suicidal tendencies have rarely been
observed. Substantial benefit has also resulted from cognitive-behavioural
therapy and similar psychotherapies.
Back to Top
|